Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957804 | 0.94 | RIPK1 (0.51) | RIPK1ATML3MBTL1POLBCCR5 | |
| SCHEMBL23022895 | 0.85 | RIPK1 (0.49) | RIPK1ATML3MBTL1POLBSLC6A2 | |
| SCHEMBL22957615 | 0.83 | RIPK1 (0.62) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22957766 | 0.80 | RIPK1 (0.55) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22957773 | 0.80 | RIPK1 (0.55) | RIPK1POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22957658 | 0.80 | RIPK1 (0.68) | RIPK1L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21216577 | 0.80 | RIPK1 (0.62) | RIPK1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12000665 | 0.79 | L3MBTL1 (0.67) | ATML3MBTL1POLBCCR5ALDH1A1 | |
| SCHEMBL22957805 | 0.79 | RIPK1 (0.54) | RIPK1L3MBTL1POLBSLC6A2SLC6A4 | |
| SCHEMBL23022888 | 0.78 | RIPK1 (0.41) | RIPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885ATM 759/4885L3MBTL1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.